Mar 13, 2020 8:00 am EDT Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020 5:30 am EDT Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Mar 3, 2020 5:30 am EST Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
Feb 6, 2020 8:00 am EST Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
Jan 13, 2020 6:30 am EST Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Dec 19, 2019 4:05 pm EST Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Dec 17, 2019 1:06 pm EST Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
Dec 9, 2019 5:30 am EST Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Nov 6, 2019 6:30 am EST Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
Oct 31, 2019 5:30 am EDT Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019